Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2017-07-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
关于微生态医疗公司与厦门大学医学院微生态研究院合作暨对外捐赠的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a cooperation and donation between the company's subsidiary and a university research institute. It includes details about the board meeting resolution approving the cooperation and donation, the impact on the company, and independent directors' opinions. There are no financial statements, earnings data, or detailed financial analysis. The document is relatively short (1654 characters) and serves as a formal announcement of a corporate action rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a management change or shareholding notification. The content is about a corporate cooperation and donation announcement, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-07-12 Chinese
关于延期回复深圳证券交易所重组问询函暨股票继续停牌的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the delay in responding to an inquiry letter from the Shenzhen Stock Exchange related to a major asset restructuring. It discusses the stock suspension, ongoing regulatory review, and the company's plans to continue coordinating responses and disclose information. The document does not contain financial statements or detailed financial data but is an update on the status of a regulatory inquiry and stock suspension related to a major restructuring. It is not a full report like an Annual Report or Interim Report, nor is it a direct announcement of voting results or management changes. It fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about the status of a corporate action and compliance with disclosure requirements.
2017-07-10 Chinese
2017年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2017 half-year performance forecast (业绩预告) for the period January 1 to June 30, 2017. It provides estimated net profit figures and explanations for performance changes but explicitly states that the forecast is preliminary and unaudited. It also mentions that detailed data will be disclosed in the 2017 half-year report. The document is short (751 characters) and serves as an earnings preview rather than a full interim report with actual financial statements. Therefore, it fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only.
2017-07-04 Chinese
关于延期回复深圳证券交易所重组问询函暨股票继续停牌的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the delay in responding to an inquiry letter from the Shenzhen Stock Exchange related to a major asset restructuring. It discusses the stock suspension, ongoing regulatory review, and the need for further verification and intermediary opinions before replying. The document does not contain financial statements or detailed financial data but is a regulatory update about the status of a restructuring process and stock suspension. It is not a full report like an Annual Report or Interim Report, nor is it a direct merger filing or voting result. It fits best as a Regulatory Filing (RNS) because it is a compliance and status update related to regulatory inquiries and stock suspension.
2017-07-03 Chinese
关于2017年股票期权激励计划内幕信息知情人买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading related to the company's 2017 stock option incentive plan. It references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange concerning insider information management and stock trading by insiders. The document details the scope and procedures of the investigation, lists individuals involved, and concludes no insider trading occurred. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a regulatory compliance report related to insider trading and stock option plans, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories and is a compliance disclosure.
2017-06-29 Chinese
2017年第二次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of a company's 2017 second extraordinary general meeting of shareholders. It details the legality and validity of the meeting procedures and resolutions passed, including voting results on various proposals. The document is not a full annual or interim report, nor is it a financial statement or earnings release. It is not a proxy solicitation or a voting results announcement per se, but a legal opinion on the meeting's conduct and resolutions. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal document related to corporate governance and shareholder meetings but does not fit other specific categories like AGM Information or Declaration of Voting Results. The document length (9123 characters) and content confirm it is a detailed legal opinion, not a brief announcement or a report publication notice.
2017-06-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.